Observational studyJournal of cancer research and clinical oncology2021
Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study.
Observational study in Journal of cancer research and clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 43 citations in OpenAlex.
- Estimating stage-specific lung cancer costs for economic evaluation of LDCT screening in Ireland: a patient-level microsimulation.BMC health services research · 2026Article
- A Bioimaging Study ofMolecular imaging and biology · 2026Article
- Evaluation of implementation of evolving practice patterns in the first-line treatment of patients with metastatic non-small cell lung cancer in Turkiye (ESTIMATE): a national, multicenter, retrospective, real-world evidence study.Future oncology (London, England) · 2025Article
- Real-world treatment patterns among advanced non-small cell lung cancer patients in the US.Innovations in pharmacy · 2025Article
- Impact of next-generation sequencing vs polymerase chain reaction testing on payer costs and clinical outcomes throughout the treatment journeys of patients with metastatic non-small cell lung cancer.Journal of managed care & specialty pharmacy · 2024Article
- Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany: a historical cohort analysis.The Lancet regional health. Europe · 2024Article
- Diagnosis, testing, treatment, and outcomes among patients with advanced non-small cell lung cancer in the United States.Cancer medicine · 2023Article
- Risk factors influencing chemotherapy compliance and survival of elderly patients with non-small cell lung cancer.African health sciences · 2023Article
- Preclinical Characterization of 22-(4'-Pyridinecarbonyl) Jorunnamycin A against Lung Cancer Cell Invasion and AngiogenesisACS pharmacology & translational science · 2023Article
- Article
- Understanding inequities in precision oncology diagnostics.Nature cancer · 2023Review
- Article
- Molecular patterns of egyptian patients with non-squamous non-small-cell lung cancers: a clinicopathological study.Journal of the Egyptian National Cancer Institute · 2023Article
- First-Line Pembrolizumab Plus Chemotherapy for Advanced Squamous NSCLC: Real-World Outcomes at U.S. Oncology Practices.JTO clinical and research reports · 2023Article
- Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012-2018.BMC pulmonary medicine · 2023Article
- Operationalising AI governance through ethics-based auditing: an industry case study.AI and ethics · 2023Article
- Biomarker Testing for Patients With Advanced/Metastatic Nonsquamous NSCLC in the United States of America, 2015 to 2021.JTO clinical and research reports · 2022Article
- Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy.Journal of clinical medicine · 2022Article
- Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis.BMC cancer · 2022Article
- Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States.Journal of managed care & specialty pharmacy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTreatments for advanced non-small cell lung cancer (NSCLC) have evolved to include targeted and immuno-oncology therapies, which have demonstrated clinical benefits in clinical trials. However, few real-world studies have evaluated these treatments in the first-line setting.
methodsAdult patients with advanced NSCLC who initiated first-line treatment with chemotherapy, targeted therapies (TT), or immuno-oncology-based regimens in the US Oncology Network (USON) between March 1, 2015, and August 1, 2018, were included and followed up through February 1, 2019. Data were sourced from structured fields of USON electronic health records. Patient and treatment characteristics were assessed descriptively, with Kaplan-Meier methods used to evaluate time-to-event outcomes, including time to treatment discontinuation (TTD) and overall survival (OS). Adjusted Cox regression analyses and inverse probability of treatment weighting (IPTW) were performed to control for covariates that may have affected treatment selection and outcomes.
resultsOf 7746 patients, 75.6% received first-line systemic chemotherapy, 11.7% received immuno-oncology monotherapies, 8.5% received TT, and 4.2% received immuno-oncology combination regimens. Patients who received immuno-oncology monotherapies had the longest median TTD (3.5 months; 95% confidence interval [CI], 2.8-4.2) and OS (19.9 months; 95% CI, 16.6-24.1). On the basis of multivariable Cox regression and IPTW, immuno-oncology monotherapy was associated with reduced risk of death and treatment discontinuation relative to other treatments.
conclusionThese results suggest that real-world outcomes in this community oncology setting improved with the introduction of immuno-oncology therapies. However, clinical benefits are limited in certain subgroups and tend to be reduced compared with clinical trial observations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.